NASDAQ$AKYA
Akoya Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Akoya reported a strong second quarter with a 53% increase in revenue and significant growth in reagent sales, driven by the continued adoption of CODEX and Phenoptics solutions.
Akoya Biosciences reported a strong second quarter, with total revenue reaching $13.1 million, a 53% increase compared to the same period last year. The company saw substantial growth in reagent sales and continued adoption of its CODEX and Phenoptics solutions.
- Total revenue for the second quarter of 2021 was $13.1 million, representing 53% growth compared to $8.6 million in the second quarter of 2020.
- Reagent sales were strong, with $4.3 million in revenue compared to $1.5 million in the second quarter of 2020.
- Gross profit was $8.1 million in the second quarter of 2021, compared to $5.3 million in the second quarter of 2020, with a gross profit margin of 62.2%.
- The company launched Advanced Biopharma Solutions (ABS) and partnered with AstraZeneca to deliver spatial biomarker-guided drug development and clinical trials services.
Headline financials
Revenue & EPS history
Akoya · Revenue · Quarterly
$13.1M
Revenue by segment
Akoya · $10.7M total across 1 segment · Q2 2021
- Product revenue$10.7M+73.3%100.0%
Forward guidance
Akoya is refining its revenue guidance for the full year 2021 to a range of $52.5 million to $53.0 million. The company anticipates revenue growth of approximately 28-30% for the third quarter of 2021 compared to the prior year quarter.
Tailwinds
- Refined revenue guidance for full year 2021 from at least $52.0 million to a range of $52.5 to $53.0 million.
- Expected revenue growth of approximately 28-30% for the third quarter of 2021 over the prior year quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports
-3.7%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-17.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+13.7%
Q4 2021
Best reaction
-31.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | +1.0% | +24.8% | +23.8% | |
| Q4 2025 | +3.8% | +9.2% | -30.7% | |
| Q3 2024 | -24.9% | -33.2% | -29.5% | |
| Q2 2024 | -9.5% | -0.9% | +5.5% | |
| Q1 2024 | -31.9% | -35.1% | -50.0% | |
| Q4 2023 | -15.4% | -17.1% | -28.1% | |
| Q3 2023 | +10.0% | +6.9% | +16.4% | |
| Q2 2023 | +0.9% | -6.5% | -23.9% | |
| Q1 2023 | -2.5% | -17.1% | -18.8% | |
| Q4 2022 | -7.3% | -17.2% | -36.6% | |
| Q3 2022 | -15.1% | — | — | |
| Q2 2022 | +5.0% | — | — | |
| Q1 2022 | -11.9% | — | — | |
| Q4 2021 | +13.7% | — | — | |
| Q3 2020 | +1.5% | — | — | |
| Q3 2021 | +0.2% | — | — | |
| Q2 2021 | -0.1% | — | — | |
| Q4 2020 | +9.5% | — | — | |
| Q1 2021 | +2.3% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro